VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

HER2 ICD peptide vaccine
Vaccine Information
  • Vaccine Name: HER2 ICD peptide vaccine
  • Target Pathogen: Cancer
  • Target Disease: Cancer
  • Type: Subunit vaccine
  • Status: Clinical trial
  • Host Species for Licensed Use: None
  • Antigen: HER-2/neu intracellular domain protein (NCT00343109)
  • Immunization Route: Intradermal injection (i.d.)
  • Description: Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Patients with HER2 positive locally advanced breast cancer can be vaccinated with a HER2 Intracellular Domain (ICD) peptide-based vaccine administered concurrently with trastuzumab. The vaccine may lead to an immune response (HER2 specific T cell immunity and/or the development of intramolecular epitope spreading). (NCT00343109)
Host Response
References
NCT00343109: Vaccine Therapy in Treating Patients Receiving Trastuzumab For HER2-Positive Stage IIIB-IV Breast Cancer [https://clinicaltrials.gov/study/NCT00343109]